Mylan Launches Generic Xeloda
Xeloda is a fluoropyrimidine indicated for metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel when further anthracycline therapy is not indicated, and with docetaxel for metastatic breast cancer after failure of prior anthracycline-containing regimen. Xeloda is also indicated as first-line treatment of metastatic colorectal carcinoma when fluoropyrimidine therapy alone is preferred, and as adjuvant treatment of Dukes' C colon cancer after complete resection of the primary tumor when fluoropyrimidine therapy alone is preferred.
Capecitabine Tablets are available in 150mg and 50mg strengths.
For more information call (800) RX-MYLAN or visit Mylan.com.